Wedbush Sees 43% Upside in Voyager Technologies as Defense and Space Plays Converge
Defense contracts and Starlab optionality highlighted.
Already have an account? Sign in.
Defense contracts and Starlab optionality highlighted.
Court orders Guardant Health to pay over $245.2M for willfully infringing TwinStrand’s DNA sequencing patents. Ongoing 6% royalties apply; Guardant will appeal.
Evercore lifts Expedia’s PT to $430 (from $375); Wedbush raises its target to $417 (from $334) following the Q2 earnings beat and raised guidance.
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.